Stay updated with breaking news from Repligen Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Repligen (NASDAQ:RGEN – Get Rating) had its price target decreased by Craig Hallum from $220.00 to $207.00 in a report released on Wednesday, The Fly reports. Craig Hallum’s target price points to a potential upside of 31.65% from the stock’s current price. Several other research analysts have also recently commented on the company. SVB Leerink […]
Repligen Co. (NASDAQ:RGEN – Get Rating) – Stock analysts at William Blair reduced their Q3 2023 earnings estimates for Repligen in a research report issued on Wednesday, May 3rd. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings of $0.52 per share for the quarter, down from their prior forecast […]
Repligen (NASDAQ:RGEN – Get Rating) issued its quarterly earnings data on Tuesday. The biotechnology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.59 by $0.05, Briefing.com reports. Repligen had a return on equity of 10.31% and a net margin of 23.20%. The company had revenue of $182.70 million during the quarter, […]
Repligen (NASDAQ:RGEN – Get Rating) had its price target lowered by Stifel Nicolaus from $225.00 to $210.00 in a research note issued to investors on Wednesday, The Fly reports. A number of other brokerages also recently weighed in on RGEN. StockNews.com initiated coverage on Repligen in a report on Thursday, March 16th. They issued a […]
Repligen (NASDAQ:RGEN – Get Rating) updated its FY23 earnings guidance on Tuesday. The company provided earnings per share guidance of $2.35-$2.42 for the period, compared to the consensus earnings per share estimate of $2.64. The company issued revenue guidance of $720-$760 million, compared to the consensus revenue estimate of $779.97 million. Wall Street Analyst Weigh […]